For lung cancer patients, getting an earlier diagnosis is crucial in creating the opportunity for accelerating treatment discussions.

Johnson & Johnson is striving toward improving outcomes for patients with lung cancer. To do that, we are innovating to revolutionize how pulmonary diseases, including lung cancer, is diagnosed with technology that can help physicians diagnose the disease earlier, as well as solutions that could treat it with precision.

The MONARCH™ Platform, a robotically assisted bronchoscopy system, improves how physicians reach and biopsy lung lesions in the periphery of the lung. The bronchoscope is designed for continuous vision throughout the procedure. It is designed to travel through the airways deep into the lungs and guide a biopsy instrument into even the most difficult to reach nodules, while maintaining vision during the most critical segment of the procedure, the biopsy.

MONARCH™ QUEST reduces CT-to-body divergence within the imaging integration workflow. Enable real-time navigation updates when near the target during bronchoscopy procedures performed with the MONARCH™ Platform via 3D imaging data directly from a CBCT system. Utilizing the MONARCH™ Platform in conjunction with Cone Beam Computed Tomography (CBCT) has demonstrated diagnostic yields of up to 91%. The MONARCH Platform’s Navigation Software uses multiple inputs, making it robust against distortion and errors.

To learn more about the MONARCH platform and important safety information please visit https://www.jnjmedtech.com/en-US/product-family/monarch